ProShare Advisors
PLX icon

ProShare Advisors’s Protalix BioTherapeutics PLX Stock Holding History

ProShare Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23K Sell
10,589
-2,548
-19% -$6.32K ﹤0.01% 1834
2025
Q4 		$23.6K Buy
13,137
+1,215
+10% +$2.48K ﹤0.01% 2013
2025
Q3 		$26.5K Sell
11,922
-2,375
-17% -$3.87K ﹤0.01% 1977
2025
Q2 		$21.2K Buy
+14,297
New +$29.2K ﹤0.01% 2066
2024
Q2 		– Sell
-12,147
Closed -$15.3K – 1963
2024
Q1 		$15.3K Buy
12,147
+1,168
+11% +$1.74K ﹤0.01% 1981
2023
Q4 		$19.5K Buy
+10,979
New +$17.1K ﹤0.01% 1920

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

ProShare Advisors's PLX Position: Q1 2026 in Review

ProShare Advisors reduced its Protalix BioTherapeutics (PLX) stake by 19% in Q1 2026, selling an estimated $6.32K and leaving 10,589 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #1834.

ProShare Advisors first reported a position in PLX in Q4 2023 and has held it in 6 quarters since. The position peaked at $26.5K in Q3 2025. 100 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • ProShare Advisors held 10,589 shares of Protalix BioTherapeutics worth $23K as of Q1 2026.
  • ProShare Advisors sold 2,548 Protalix BioTherapeutics shares in Q1 2026, an estimated $6.32K.
  • Protalix BioTherapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1834 holding.
  • ProShare Advisors first reported a position in Protalix BioTherapeutics in Q4 2023 and has held it in 6 quarters since.
  • ProShare Advisors's Protalix BioTherapeutics position peaked at $26.5K in Q3 2025.
  • 100 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.